吡托布鲁替尼对比艾德拉尼/利妥昔单抗或苯达莫司汀/利妥昔单抗在共价布鲁顿酪氨酸激酶抑制剂经治的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤中的III期试验(BRUIN CLL-321)
BRUIN CLL-321是一项开放标签随机III期研究,仅纳入既往接受过共价BTK抑制剂治疗的复发/难治性CLL/SLL患者,随机接受吡托布鲁替尼或研究者选择的艾德拉尼/利妥昔单抗或苯达莫司汀/利妥昔单抗。吡托布鲁替尼组中位PFS为14个月,对照组为8.7个月(HR 0.54,P=0.0002),中位TTNT为24个月 vs 10.9个月(HR 0.37),且≥3级治疗中出现的不良事件发生率更低(57.7% vs 73.4%)。
要点
- 吡托布鲁替尼较艾德拉尼/利妥昔单抗或苯达莫司汀/利妥昔单抗延长PFS(中位14个月 vs 8.7个月,HR 0.54)。
- 吡托布鲁替尼延长TTNT(中位24个月 vs 10.9个月,HR 0.37)。
- 吡托布鲁替尼≥3级治疗中出现的不良事件发生率更低(57.7% vs 73.4%)。
核心结论
- 在仅纳入共价BTK抑制剂经治的CLL/SLL患者中,吡托布鲁替尼较艾德拉尼/利妥昔单抗或苯达莫司汀/利妥昔单抗改善PFS和TTNT,并表现出良好的耐受性。
研究设计与样本
- BRUIN CLL-321是一项开放标签、随机III期研究,仅纳入既往接受过共价BTK抑制剂治疗的复发/难治性CLL/SLL患者。
- 患者按1:1随机接受吡托布鲁替尼200 mg每日一次(n=119)或研究者选择的艾德拉尼/利妥昔单抗(n=82)或苯达莫司汀/利妥昔单抗(n=37),共238例,按既往维奈克拉使用和del(17p)分层。
- 主要终点为独立评审委员会评估的PFS,次要终点包括TTNT、OS和安全性;主要PFS终点在主要分析时(2023年8月29日)达到,最终OS分析(2024年8月29日)更新结果报告。
主要发现
- PFS的HR为0.54(95%CI 0.39至0.75;P=0.0002),吡托布鲁替尼组中位PFS为14个月(95%CI 11.2至16.6),对照组为8.7个月(95%CI 8.1至10.4)。
- 未校正OS的HR为1.09(95%CI 0.68至1.75;P=0.7202),18个月OS率吡托布鲁替尼组为73.4%(95%CI 63.9至80.7),对照组为70.8%(95%CI 60.9至78.7)。
- 中位TTNT吡托布鲁替尼组为24个月(95%CI 17.8至29.7),对照组为10.9个月(95%CI 8.7至12.5),HR为0.37(95%CI 0.25至0.52)。
- 中位随访17.2个月时,≥3级治疗中出现的不良事件吡托布鲁替尼组为57.7%,对照组为73.4%。
- 因不良事件终止治疗的患者吡托布鲁替尼组为20例(17.2%),对照组为38例(34.9%)。
临床怎么用
- 原文结论为吡托布鲁替尼较艾德拉尼/利妥昔单抗或苯达莫司汀/利妥昔单抗改善PFS和TTNT并表现出良好耐受性,未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted exclusively in patients with R/R chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) previously treated with cBTKi, and compared pirtobrutinib with investigator's choice (IC) of idelalisib/rituximab (IdelaR) or bendamustine/rituximab (BR). METHODS: Patients were randomly assigned 1:1 to receive pirtobrutinib (200 mg once daily) or IC of IdelaR or BR, and were stratified by previous use of venetoclax and del(17p). The primary end point was independent review committee-assessed progression-free survival (PFS). Secondary end points included time to next treatment or death (TTNT), overall survival (OS), and safety. The primary PFS end point was met at the time of the primary analysis (August 29, 2023), and updated results are reported from the final OS analysis (August 29, 2024). RESULTS: A total of 238 patients were randomly assigned to receive pirtobrutinib (n = 119) or IC (n = 119; IdelaR [n = 82], BR [n = 37]). The PFS hazard ratio (HR) was 0.54 ([95% CI, 0.39 to 0.75]; P = .0002), with a median PFS of 14 months (95% CI, 11.2 to 16.6) in the pirtobrutinib group and 8.7 months (95% CI, 8.1 to 10.4) with IC. The unadjusted OS HR was 1.09 ([95% CI, 0.68 to 1.75]; P = .7202), and 18-month OS rate was 73.4% (95% CI, 63.9 to 80.7) in the pirtobrutinib group and 70.8% (95% CI, 60.9 to 78.7) with IC. Median TTNT was 24 months (95% CI, 17.8 to 29.7) with pirtobrutinib versus 10.9 months (95% CI, 8.7 to 12.5) with IC (HR, 0.37 [95% CI, 0.25 to 0.52]). At a median follow-up of 17.2 months, grade ≥3 treatment-emergent adverse events (AEs) were lower with pirtobrutinib (57.7%) than IC (73.4%). Treatment discontinuation due to AE occurred in 20 (17.2%) patients receiving pirtobrutinib and 38 (34.9%) patients receiving IC. CONCLUSION: Pirtobrutinib improved PFS and TTNT, and demonstrated favorable tolerability, versus IdelaR/BR in exclusively cBTKi pretreated patients with CLL/SLL.
引用
- Sharman JP, Munir T, Grosicki S, et al. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025. PMID: 40479620. doi:10.1200/JCO-25-00166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。